Episode Description
Studies show most people regain up to 80% of their weight after stopping GLP-1 medications like Wegovy, Zepbound, Mounjaro, or Ozempic. But it doesn't have to be that way. Dr. Holly Wyatt and Dr. Jim Hill, leading weight loss maintenance researchers and one of the co-founders of the National Weight Control Registry, share their science-backed strategies for keeping weight off when you stop the medication. They break down the three essential pillars—nutrition, exercise, and mindset—and explain why the medications are a "fix" not a cure. Whether you're planning to taper off, considering staying on long-term, or exploring your options, this conversation offers practical plays you can implement to protect your progress.
About Dr. Holly Wyatt and Dr. Jim Hill:
Two of the world’s leading experts on long-term weight management have just released their book, Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight.
Resources:
Website:
https://www.weightwisdom.com
Instagram:
Dr. Wyatt: @drhollywyatt
Facebook:
https://www.facebook.com/stateofslim
LinkedIn:
Dr. Wyatt: https://linkedin.com/in/holly-wyatt-a47a82b2
Dr. Hill: https://linkedin.com/in/james-hill-b156456
Want to Learn More about GLP-1 Hub?
Join the Steady State newsletter and get a FREE 7-day meal plan + weekly support and strategy to optimize your journey:
Join the membership:
https://glp-1hub.com/membership
Visit our GLP-1 Hub store:
Want to connect more with GLP-1 Hub?
Instagram: https://www.instagram.com/glp1hub
Tiktok: https://www.tiktok.com/@glp1hub
YouTube: https://www.youtube.com/@glp-1hub
*Some of the links shared are affiliate links. When you make a purchase, I will receive a small commission at no cost to you. Thank you for supporting the show.
*The content of this show is for informational purposes only and does not constitute medical advice. The goal of this show is to provide various points of view about GLP-1 Medications. The personal and professional opinion of the guests and their content does not necessarily reflect the opinion of Ana Reisdorf or GLP-1 Hub.